Spero

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Retrieved on: 
Wednesday, March 6, 2024

ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

Key Points: 
  • ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458, or click on this Link and request a return call.
  • The audio webcast can be accessed on the "Events and Presentations" page under the “Connect” tab of the Company's website at www.sperotherapeutics.com .
  • The archived webcast will also be available on Spero's website for 30 days following the call.

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

Retrieved on: 
Monday, February 26, 2024

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA.
  • Details are as follows:
    The webcasts for this event may also be accessed through Spero Therapeutics’ website ( www.sperotherapeutics.com ) on the “Events and Presentations” page under the “Connect” tab.
  • Replays will be available on the website following the conclusion of each event.

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Retrieved on: 
Friday, January 5, 2024

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need, today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024.

Key Points: 
  • Entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreement
    CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need, today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024.
  • “We look forward to another productive year for Spero in 2024, having achieved important clinical and regulatory milestones over the past twelve months,” said Sath Shukla, President, and CEO of Spero Therapeutics.
  • Our Phase 2a trial of SPR720 in nontuberculous mycobacterial pulmonary disease is on track, and we look forward to reporting topline data, which is expected in the second half of 2024.
  • The trial is expected to enroll up to 35 treatment-naïve or treatment-experienced non-refractory participants with NTM-PD, due to Mycobacterium avium complex.

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, January 2, 2024

Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.

Key Points: 
  • Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.
  • “First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program,” said Sath Shukla, President and CEO of Spero Therapeutics.
  • "We are developing Tebipenem HBr to potentially be the first oral broad-spectrum carbapenem in the U.S. for use in patients with cUTI.
  • The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Retrieved on: 
Monday, November 6, 2023

ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.

Key Points: 
  • ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13741831, or click on this link and request a return call.
  • The audio webcast can be accessed on the "Events and Presentations" page under the “Connect” tab of the Company's website at www.sperotherapeutics.com .
  • The archived webcast will also be available on Spero's website for 30 days following the call.

Spero Therapeutics to Present at Upcoming November Investor Conferences

Retrieved on: 
Wednesday, November 1, 2023

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at the Lotte New York Palace in New York, NY, on November 8-9, 2023 and will present and be available for one-on-one meetings at the 6th Annual Evercore ISI HealthCONx Conference to be held at the Kimpton EPIC Miami Hotel in Miami, FL, on November 28-30, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at the Lotte New York Palace in New York, NY, on November 8-9, 2023 and will present and be available for one-on-one meetings at the 6th Annual Evercore ISI HealthCONx Conference to be held at the Kimpton EPIC Miami Hotel in Miami, FL, on November 28-30, 2023.
  • Details are as follows:
    The webcast for the Evercore ISI event may also be accessed through Spero Therapeutics’ website ( www.sperotherapeutics.com ) on the “Events and Presentations” page under the “Connect” tab.
  • Replays will be available on the website following the conclusion of each event.

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Retrieved on: 
Wednesday, November 1, 2023

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer.
  • Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company’s Interim CFO since August 1, 2023.
  • Esther brings a proven track record in corporate finance, from both industry and Wall Street, bringing expertise in life science growth strategies, investor relations, financing, and M&A,” said Sath Shukla, Spero’s Chief Executive Officer.
  • Ms. Rajavelu will formally assume the role of Principal Financial Officer on the day after the filing of such Form 10-Q.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, October 31, 2023

The RSUs are being granted as inducements material to the new employee, becoming an employee of Spero in accordance with Nasdaq Listing Rule5635(c)(4).

Key Points: 
  • The RSUs are being granted as inducements material to the new employee, becoming an employee of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals, entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The RSUs will vest in four equal annual installments beginning on November 1, 2024, subject to the employee's continued employment with Spero on such vesting dates.
  • The RSUs are subject to the terms and conditions of the 2019 Inducement Plan and an RSU agreement covering the grant.

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, November 3, 2023

Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
  • Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
  • On March 31, 2022, Spero issued a press release announcing the Company’s fourth quarter and full year 2021 financial results.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Retrieved on: 
Thursday, October 12, 2023

Highlights of the New Distribution Partnership:

Key Points: 
  • Highlights of the New Distribution Partnership:
    Superlatus has entered into a strategic collaboration with Rainforest, a leading Direct Store Delivery distributor serving the North Atlantic, Northeast, Midwest, and Mid-Atlantic regions, specializing in better-for-you brands.
  • Superlatus and Rainforest will join forces to introduce Superlatus' products to an extensive network of over 5,000 retail locations, including prominent names such as Whole Foods, Kroger, Moms Organics, ShopRite, Fairway, and more.
  • Rainforest's partnership will provide Superlatus with a distribution ally, enabling increased reach in the high-potential Tri-State area, home to over 33% of the country's consumers.
  • Superlatus CEO, Tim Alford, expressed his enthusiasm about the supplier agreement with Rainforest, emphasizing what this expanded distribution offers Superlatus.